A new at-home urine test detected 92% of bladder cancers in a study, potentially offering faster, less invasive cancer detection.
Veracyte has acquired Convergent Genomics in a transaction valued at up to $180 million, adding the UroAmp urinary tumor DNA ...
A SIMPLE urine test can detect nine out of ten bladder cancers, according to results from an NHS trial. It could be done at home and save tens of thousands of patients per year from the discomfort ...
In a multi-institutional study published in the European Urology journal, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher ...
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journeySOUTH SAN FRANCISCO, Calif., Sept. 14, ...
The approach builds on earlier research showing that mutations in bladder-cancer-related genes can be identified in urinary DNA. An earlier study of targeted urinary DNA sequencing also found that ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A new study has found that the use of a specific at-home urine test could detect bladder cancer with accuracy. Here are its implications and why this test is a medical breakthrough.
Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted bladder-preservation approach involving neoadjuvant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results